Background: Treatment of short children born small for gestational age (SGA) with recombinant human growth hormone (r-hGH) increases growth velocity during childhood. As in other indications, the growth velocity in these patients is more marked during the first year of treatment and then decreases. This study was undertaken to evaluate the efficacy of different r-hGH treatment schedules (67 µg/kg/day in a discontinuous or continuous regimen) during the second year of r-hGH treatment by comparing height velocity changes and total gain of height over a 4-year period. Methods: 58 growth-retarded SGA children aged 2–5 years were randomized to a TOTO regimen [4 years alternating treatment (T) and observation (O), n = 30] or a TTOO regimen (2 years’ treatment, followed by 2 years’ observation, n = 28). Height velocity (HV) and total height gain were assessed during the 4-year study. Results: In both groups, HV and HV standard deviation score (HV-SDSCA) increased during treatment and decreased during observation periods. Interruption of treatment in the TOTO group did not result in a better gain in height standard deviation score (H-SDSCA) when compared with the TTOO group. After 4 years of study, the gain in H-SDSCA was 1.4 ± 01 in the TOTO group and 1.6 ± 0.2 in the TTOO group leading to a mean height of –2.0 ± 1.0 SDS and –2.0 ± 0.8 SDS, respectively. The rate of bone maturation was similar in the two groups. Conclusions: In short SGA children, TOTO and TTOO regimens produced significant improvements in growth during r-hGH treatment. However, treatment interruption after 1 year did not influence the overall gain in height SDS when compared with 2 years’ continuous treatment.

Keywords:
Small for gestational age, Growth hormone treatment, Randomized trial
1.
Lapillonne A, Peretti N, Ho PS, Claris O, Salle BL: Aetiology, morphology and body composition of infants born small for gestational age. Acta Paediatr 1997;423(suppl):173–176.
2.
Karlberg J, Albertsson-Wikland K: Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 1995;38:733–739.
3.
Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL: Children born small for gestational age: do they catch up? Pediatr Res 1995;38:267–271.
4.
Albertsson-Wikland K, Karlberg J: Natural growth in children born small for gestational age with and without catch-up growth. Acta Paediatr 1994;399(suppl):64–70.
5.
Luo ZC, Albertsson-Wikland K, Karlberg J: Length and body mass index at birth and target height influences on patterns of postnatal growth in children born small for gestational age. Pediatrics 1998;102:E72.
6.
Leger J, Levy-Marchal C, Bloch J, Pinet A, Chevenne D, Porquet D, Collin D, Czernichow P: Reduced final height and indications for insulin resistance in 20 year olds small for gestational age: regional cohort study. BMJ 1997;315:341–345.
7.
Fjellestad-Paulsen A, Czernichow P, Brauner R, Bost M, Colle M, Lebouc JY, Lecornu M, Leheup B, Limal JM, Raux MC, Toublanc JE, Rappaport R: Three-year data from a comparative study with recombinant human growth hormone in the treatment of short stature in young children with intrauterine growth retardation. Acta Paediatr 1998;87:511–517.
8.
Sas T, de Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 1999;84:3064–3070.
9.
De Zegher F, Butenand O, Chatelain P, Albertsson-Wikland K, Jonsson B, Lofstrom A, Chaussain JL: Growth hormone treatment of short children born small for gestational age: reappraisal of the rate of bone maturation over 2 years and meta-analysis of height over 4 years. Acta Paediatr 1997;324(suppl):207–212.
10.
De Zegher F, Albertsson-Wikland K, Wollmann HA, Chatelain P, Chaussain JL, Lofstrom A, Jonsson B, Rosenfeld RG: Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab 2000;85:2816–2821.
11.
Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose response GH trial. J Clin Endocrinol Metab 2003;88:3584–3590.
12.
Sempé M, Pédron G, Roy-Pernot MP: Auxologie, méthodes et séquences. Paris, Theraplix, 1979.
13.
Leroy B, Lefort F: A propos du poids et de la taille des nouveau-nés à la naissance. Rev Fr Gynécol Obstét 1971;66:391–396.
14.
Dahlgren J, Albertsson-Wikland K, on the behalf of the Swedish study group for growth hormone treatment: Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 2005;57:216–222.
15.
Ranke M, Lindberg A, Cowell CT, Albertsson-Wikland K, Reiter EO, Wilton P, Price DA, on the behalf of the KIGS international board: Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab 2003;88:125–131.
16.
Chanoine JP, Vandershueren-Lodeweyckx M, Maes M, Thiry-Counson G, Craen M, Van Vliet G: Growth hormone (GH) treatment in short normal children: absence of influence of time of injection and resistance to GH autofeedback. J Clin Endocrinol Metab 1991;73:1269–1275.
17.
Mosier HD, Dearden LC, Jansons RA, Hill RR: Cartilage sulfation during catch-up growth after fasting in rats. Endocrinology 1978;102:386–392.
18.
Kastrup KW, Christiansen JS, Andersen JK, Orskov H: Increased growth rate following transfer to daily subcutaneous administration from three weekly intramuscular injections of hGH in growth hormone deficient children. Acta Endocrinol 1983;104:148–152.
19.
Yokoya S, Araki K, Igarashi Y, Hohno H, Nishi Y, Hasegawa Y, Fujita K, Ivatani N, Tachibana K, Ohyama Y, Seino Y, Satoh M, Fujieda K, Tanaka T: High-dose growth hormone (GH) treatment in prepubertal GH-deficient children. Acta Paediatr Suppl 1999;428:76–79.
20.
Wasniewska M, De Luca F, Bergamaschi R, Guarneri MP, Mazzanti L, Matarazzo P, Petri A, Crisafulli G, Salzano G, Lombardo F: Early treatment with GH alone in Turner syndrome: prepubertal catch-up growth and waning effect. Eur J Endocrinol 2004;151:567–572.
21.
Carel JC, Mathivon L, Gendrel C, Ducret JP, Chaussain JL: Near normalization of final height with adapted doses of growth hormone in Turner’s syndrome. J Clin Endocrinol Metab 1998;83:1462–1466.
22.
Van Teunenbroek A, De Muinck Keizer-Schrama S, Stijnen T, Jansen M, Otten BJ, Delamarre-Van de Waal H, Vulsma T, Wit JM, Rouwé CW, Reeser M, Gosen JJ, Rongen-Werterlaken C, Drop SLS: Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. J Clin Endocrinol Metab 1996;81:4013–4021.
23.
Fjellestad-Paulsen A, Simon D, Czernichow P: Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment. J Clin Endocrinol Metab 2004;89:1234–1239.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.